These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 35902282)

  • 1. Engineering ACE2 decoy receptors to combat viral escapability.
    Arimori T; Ikemura N; Okamoto T; Takagi J; Standley DM; Hoshino A
    Trends Pharmacol Sci; 2022 Oct; 43(10):838-851. PubMed ID: 35902282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High activity of an affinity-matured ACE2 decoy against Omicron SARS-CoV-2 and pre-emergent coronaviruses.
    Sims JJ; Lian S; Meggersee RL; Kasimsetty A; Wilson JM
    PLoS One; 2022; 17(8):e0271359. PubMed ID: 36006993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.
    Kuba K; Yamaguchi T; Penninger JM
    Front Immunol; 2021; 12():732690. PubMed ID: 35003058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a Novel ACE2-Based Therapeutic with Enhanced Rather than Reduced Activity against SARS-CoV-2 Variants.
    Ferrari M; Mekkaoui L; Ilca FT; Akbar Z; Bughda R; Lamb K; Ward K; Parekh F; Karattil R; Allen C; Wu P; Baldan V; Mattiuzzo G; Bentley EM; Takeuchi Y; Sillibourne J; Datta P; Kinna A; Pule M; Onuoha SC
    J Virol; 2021 Sep; 95(19):e0068521. PubMed ID: 34287040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble ACE2 as a potential therapy for COVID-19.
    Krishnamurthy S; Lockey RF; Kolliputi N
    Am J Physiol Cell Physiol; 2021 Mar; 320(3):C279-C281. PubMed ID: 33502950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection.
    Miller A; Leach A; Thomas J; McAndrew C; Bentley E; Mattiuzzo G; John L; Mirazimi A; Harris G; Gamage N; Carr S; Ali H; Van Montfort R; Rabbitts T
    Sci Rep; 2021 May; 11(1):10617. PubMed ID: 34012108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension.
    Fuchs E; Rudnik-Jansen I; Dinesen A; Selnihhin D; Mandrup OA; Thiam K; Kjems J; Pedersen FS; Howard KA
    Acta Biomater; 2022 Nov; 153():411-418. PubMed ID: 36162760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ACE2-based decoy receptors for SARS coronavirus 2.
    Jing W; Procko E
    Proteins; 2021 Sep; 89(9):1065-1078. PubMed ID: 33973262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection.
    Feng F; Chen J; Zhao J; Li Y; Li M; Sun C
    Viruses; 2021 Nov; 13(11):. PubMed ID: 34835049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-guided glyco-engineering of ACE2 for improved potency as soluble SARS-CoV-2 decoy receptor.
    Capraz T; Kienzl NF; Laurent E; Perthold JW; Föderl-Höbenreich E; Grünwald-Gruber C; Maresch D; Monteil V; Niederhöfer J; Wirnsberger G; Mirazimi A; Zatloukal K; Mach L; Penninger JM; Oostenbrink C; Stadlmann J
    Elife; 2021 Dec; 10():. PubMed ID: 34927585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2.
    Chan KK; Dorosky D; Sharma P; Abbasi SA; Dye JM; Kranz DM; Herbert AS; Procko E
    Science; 2020 Sep; 369(6508):1261-1265. PubMed ID: 32753553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Broadly Effective ACE2 Decoy Proteins Protect Mice from Lethal SARS-CoV-2 Infection.
    Lu M; Yao W; Li Y; Ma D; Zhang Z; Wang H; Tang X; Wang Y; Li C; Cheng D; Lin H; Yin Y; Zhao J; Zhong G
    Microbiol Spectr; 2023 Aug; 11(4):e0110023. PubMed ID: 37395664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.
    Glasgow A; Glasgow J; Limonta D; Solomon P; Lui I; Zhang Y; Nix MA; Rettko NJ; Zha S; Yamin R; Kao K; Rosenberg OS; Ravetch JV; Wiita AP; Leung KK; Lim SA; Zhou XX; Hobman TC; Kortemme T; Wells JA
    Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28046-28055. PubMed ID: 33093202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Generation of enzymatically competent SARS-CoV-2 decoy receptor ACE2-Fc in glycoengineered Nicotiana benthamiana.
    Castilho A; Schwestka J; Kienzl NF; Vavra U; Grünwald-Gruber C; Izadi S; Hiremath C; Niederhöfer J; Laurent E; Monteil V; Mirazimi A; Wirnsberger G; Stadlmann J; Stöger E; Mach L; Strasser R
    Biotechnol J; 2021 Jun; 16(6):e2000566. PubMed ID: 33481336
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions.
    Day CJ; Bailly B; Guillon P; Dirr L; Jen FE; Spillings BL; Mak J; von Itzstein M; Haselhorst T; Jennings MP
    mBio; 2021 Mar; 12(2):. PubMed ID: 33785634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency.
    Leach A; Ilca FT; Akbar Z; Ferrari M; Bentley EM; Mattiuzzo G; Onuoha S; Miller A; Ali H; Rabbitts TH
    Antiviral Res; 2021 Oct; 194():105147. PubMed ID: 34375715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humanized COVID-19 decoy antibody effectively blocks viral entry and prevents SARS-CoV-2 infection.
    Huang KY; Lin MS; Kuo TC; Chen CL; Lin CC; Chou YC; Chao TL; Pang YH; Kao HC; Huang RS; Lin S; Chang SY; Yang PC
    EMBO Mol Med; 2021 Jan; 13(1):e12828. PubMed ID: 33159417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utilizing noncatalytic ACE2 protein mutant as a competitive inhibitor to treat SARS-CoV-2 infection.
    Liu S; Chen H; Chen X; Luo N; Peraramelli S; Gong X; Zhang MJ; Ou L
    Front Immunol; 2024; 15():1365803. PubMed ID: 38646520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
    Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
    J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.